Press "Enter" to skip to content

Novartis’s pricing might be tested with costly eye therapy

Novartis’s price-setting muscle is about to be tested after it won European Union approval for a blindness-fighting gene therapy whose $850,000 list cost in the United States has been labeled too expensive by some groups.

Original source: http://feeds.reuters.com/~r/reuters/INhealth/~3/Vzaw2EtE8fo/novartiss-pricing-might-be-tested-with-costly-eye-therapy-idINKCN1NS0FM

Also Read:   Smoking bans tied to lower blood pressure in non-smokers